{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:02:00Z","timestamp":1794024120716,"version":"4.8.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41590-025-02309-1","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T09:07:34Z","timestamp":1760519254000},"page":"2045-2058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Influenza vaccine based on AS03-adjuvanted chimeric HA induces long-lived stalk-specific plasma cells in bone marrow and lymph nodes of nonhuman primates"],"prefix":"10.1038","volume":"26","author":[{"given":"Akil","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany M.","family":"Styles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Nicol\u00e1s","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3075-755X","authenticated-orcid":false,"given":"Gregory K.","family":"Tharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasey","family":"Stokdyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anass","family":"Abbad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Strohmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara T.","family":"Richey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uchurappa","family":"Mala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-2609","authenticated-orcid":false,"given":"Julianna","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6049-0684","authenticated-orcid":false,"given":"Carl W.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7991-614X","authenticated-orcid":false,"given":"Rustom","family":"Antia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Palese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-3769","authenticated-orcid":false,"given":"Andrew B.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5061-8296","authenticated-orcid":false,"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":false,"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9591-2621","authenticated-orcid":false,"given":"Rafi","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6309-6797","authenticated-orcid":false,"given":"Rama R.","family":"Amara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2309_CR1","unstructured":"Influenza (seasonal). World Health Organization https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal) (2024)."},{"key":"2309_CR2","unstructured":"CDC seasonal flu vaccine effectiveness studies. Centers for Disease Control and Prevention https:\/\/www.cdc.gov\/flu-vaccines-work\/php\/effectiveness-studies\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/flu\/vaccines-work\/effectiveness-studies.htm (2024)."},{"key":"2309_CR3","doi-asserted-by":"crossref","first-page":"a038489","DOI":"10.1101\/cshperspect.a038489","volume":"10","author":"M Wille","year":"2020","unstructured":"Wille, M. & Holmes, E. C. The ecology and evolution of influenza viruses. Cold Spring Harb. Perspect. Med. 10, a038489 (2020).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2309_CR4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41579-023-00945-8","volume":"21","author":"AX Han","year":"2023","unstructured":"Han, A. X., de Jong, S. P. J. & Russell, C. A. Co-evolution of immunity and seasonal influenza viruses. Nat. Rev. Microbiol. 21, 805\u2013817 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"2309_CR5","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/v11050458","volume":"11","author":"R Du","year":"2019","unstructured":"Du, R., Cui, Q. & Rong, L. Competitive cooperation of hemagglutinin and neuraminidase during influenza A virus entry. Viruses 11, 458 (2019).","journal-title":"Viruses"},{"key":"2309_CR6","doi-asserted-by":"crossref","first-page":"a038638","DOI":"10.1101\/cshperspect.a038638","volume":"11","author":"SJ Gamblin","year":"2021","unstructured":"Gamblin, S. J. et al. Hemagglutinin structure and activities. Cold Spring Harb. Perspect. Med. 11, a038638 (2021).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2309_CR7","doi-asserted-by":"crossref","first-page":"e129035","DOI":"10.1172\/jci.insight.129035","volume":"4","author":"S Jegaskanda","year":"2019","unstructured":"Jegaskanda, S. et al. Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines. JCI Insight 4, e129035 (2019).","journal-title":"JCI Insight"},{"key":"2309_CR8","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1093\/infdis\/jiy696","volume":"219","author":"SJ Zost","year":"2019","unstructured":"Zost, S. J., Wu, N. C., Hensley, S. E. & Wilson, I. A. Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens. J. Infect. Dis. 219, S38\u2013S45 (2019).","journal-title":"J. Infect. Dis."},{"key":"2309_CR9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0092-8674(82)90135-0","volume":"31","author":"AJ Caton","year":"1982","unstructured":"Caton, A. J., Brownlee, G. G., Yewdell, J. W. & Gerhard, W. The antigenic structure of the influenza virus A\/PR\/8\/34 hemagglutinin (H1 subtype). Cell 31, 417\u2013427 (1982).","journal-title":"Cell"},{"key":"2309_CR10","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1016\/j.vaccine.2024.04.037","volume":"42","author":"JL Mart\u00ednez","year":"2024","unstructured":"Mart\u00ednez, J. L. et al. The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex. Vaccine 42, 3365\u20133373 (2024).","journal-title":"Vaccine"},{"key":"2309_CR11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28706-1","volume":"8","author":"E Kirkpatrick","year":"2018","unstructured":"Kirkpatrick, E., Qiu, X., Wilson, P. C., Bahl, J. & Krammer, F. The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci. Rep. 8, 10432 (2018).","journal-title":"Sci. Rep."},{"key":"2309_CR12","volume":"1","author":"T Aydillo","year":"2020","unstructured":"Aydillo, T. et al. Pre-existing hemagglutinin stalk antibodies correlate with protection of lower respiratory symptoms in flu-infected transplant patients. Cell Rep. Med. 1, 100130 (2020).","journal-title":"Cell Rep. Med."},{"key":"2309_CR13","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41591-019-0463-x","volume":"25","author":"S Ng","year":"2019","unstructured":"Ng, S. et al. Novel correlates of protection against pandemic H1N1 influenza A virus infection. Nat. Med. 25, 962\u2013967 (2019).","journal-title":"Nat. Med."},{"key":"2309_CR14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.coviro.2013.07.007","volume":"3","author":"F Krammer","year":"2013","unstructured":"Krammer, F. & Palese, P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 3, 521\u2013530 (2013).","journal-title":"Curr. Opin. Virol."},{"key":"2309_CR15","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1128\/JVI.00641-13","volume":"87","author":"F Krammer","year":"2013","unstructured":"Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542\u20136550 (2013).","journal-title":"J. Virol."},{"key":"2309_CR16","doi-asserted-by":"crossref","first-page":"E2514","DOI":"10.1073\/pnas.1402766111","volume":"111","author":"VV Mallajosyula","year":"2014","unstructured":"Mallajosyula, V. V. et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl Acad. Sci. USA 111, E2514\u2013E2523 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2309_CR17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106\u2013114 (2021).","journal-title":"Nat. Med."},{"key":"2309_CR18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1473-3099(19)30393-7","volume":"20","author":"DI Bernstein","year":"2020","unstructured":"Bernstein, D. I. et al. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infect. Dis. 20, 80\u201391 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"2309_CR19","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/cid\/ciw816","volume":"64","author":"JM Ferdinands","year":"2017","unstructured":"Ferdinands, J. M. et al. Intraseason waning of influenza vaccine protection: evidence from the US Influenza Vaccine Effectiveness Network, 2011\u201312 through 2014\u201315. Clin. Infect. Dis. 64, 544\u2013550 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"2309_CR20","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/cid\/ciy770","volume":"68","author":"GT Ray","year":"2019","unstructured":"Ray, G. T. et al. Intraseason waning of influenza vaccine effectiveness. Clin. Infect. Dis. 68, 1623\u20131630 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"2309_CR21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","volume":"8","author":"MK Slifka","year":"1998","unstructured":"Slifka, M. K., Antia, R., Whitmire, J. K. & Ahmed, R. Humoral immunity due to long-lived plasma cells. Immunity 8, 363\u2013372 (1998).","journal-title":"Immunity"},{"key":"2309_CR22","doi-asserted-by":"crossref","first-page":"eabb1025","DOI":"10.1126\/sciimmunol.abb1025","volume":"5","author":"SP Kasturi","year":"2020","unstructured":"Kasturi, S. P. et al. 3M-052, a synthetic TLR-7\/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. Sci. Immunol. 5, eabb1025 (2020).","journal-title":"Sci. Immunol."},{"key":"2309_CR23","doi-asserted-by":"crossref","first-page":"eadg7015","DOI":"10.1126\/sciimmunol.adg7015","volume":"8","author":"NK Routhu","year":"2023","unstructured":"Routhu, N. K. et al. Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates. Sci. Immunol. 8, eadg7015 (2023).","journal-title":"Sci. Immunol."},{"key":"2309_CR24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao, T. et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct. Target. Ther. 8, 283 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2309_CR25","doi-asserted-by":"crossref","first-page":"17957","DOI":"10.1073\/pnas.1906613117","volume":"117","author":"AH Ellebedy","year":"2020","unstructured":"Ellebedy, A. H. et al. Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans. Proc. Natl Acad. Sci. USA 117, 17957\u201317964 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2309_CR26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2009.10.017","volume":"28","author":"I Leroux-Roels","year":"2010","unstructured":"Leroux-Roels, I. et al. Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28, 849\u2013857 (2010).","journal-title":"Vaccine"},{"key":"2309_CR27","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1086\/652701","volume":"201","author":"JM Langley","year":"2010","unstructured":"Langley, J. M. et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1\/2 trial in adults. J. Infect. Dis. 201, 1644\u20131653 (2010).","journal-title":"J. Infect. Dis."},{"key":"2309_CR28","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-018-0076-2","volume":"3","author":"S Khurana","year":"2018","unstructured":"Khurana, S. et al. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. NPJ Vaccines 3, 40 (2018).","journal-title":"NPJ Vaccines"},{"key":"2309_CR29","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00308-5","volume":"6","author":"A Madsen","year":"2021","unstructured":"Madsen, A., Jul-Larsen, \u00c5, Trieu, M. C., Krammer, F. & Cox, R. J. Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: dissecting the HA specific antibody response. NPJ Vaccines 6, 45 (2021).","journal-title":"NPJ Vaccines"},{"key":"2309_CR30","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adi8039","volume":"9","author":"L Grigoryan","year":"2024","unstructured":"Grigoryan, L. et al. AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans. Sci. Immunol. 9, eadi8039 (2024).","journal-title":"Sci. Immunol."},{"key":"2309_CR31","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1473-3099(21)00764-7","volume":"22","author":"S Sridhar","year":"2022","unstructured":"Sridhar, S. et al. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Lancet Infect. Dis. 22, 636\u2013648 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"2309_CR32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/ars.2010.3241","volume":"14","author":"I Messaoudi","year":"2011","unstructured":"Messaoudi, I., Estep, R., Robinson, B. & Wong, S. W. Nonhuman primate models of human immunology. Antioxid. Redox Signal. 14, 261\u2013273 (2011).","journal-title":"Antioxid. Redox Signal."},{"key":"2309_CR33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fimmu.2014.00316","volume":"5","author":"C Vaure","year":"2014","unstructured":"Vaure, C. & Liu, Y. A comparative review of Toll-like receptor 4 expression and functionality in different animal species. Front. Immunol. 5, 316 (2014).","journal-title":"Front. Immunol."},{"key":"2309_CR34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41577-018-0005-7","volume":"18","author":"JD Estes","year":"2018","unstructured":"Estes, J. D., Wong, S. W. & Brenchley, J. M. Nonhuman primate models of human viral infections. Nat. Rev. Immunol. 18, 390\u2013404 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2309_CR35","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09737","volume":"470","author":"SP Kasturi","year":"2011","unstructured":"Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543\u2013547 (2011).","journal-title":"Nature"},{"key":"2309_CR36","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.3389\/fimmu.2019.02214","volume":"10","author":"AA Aradottir Pind","year":"2019","unstructured":"Aradottir Pind, A. A. et al. Adjuvants enhance the induction of germinal center and antibody secreting cells in spleen and their persistence in bone marrow of neonatal mice. Front. Immunol. 10, 2214 (2019).","journal-title":"Front. Immunol."},{"key":"2309_CR37","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","volume":"29","author":"S Morel","year":"2011","unstructured":"Morel, S. et al. Adjuvant system AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29, 2461\u20132473 (2011).","journal-title":"Vaccine"},{"key":"2309_CR38","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1016\/j.cell.2021.05.039","volume":"184","author":"F Wimmers","year":"2021","unstructured":"Wimmers, F. et al. The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. Cell 184, 3915\u20133935 (2021).","journal-title":"Cell"},{"key":"2309_CR39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41590-024-02036-z","volume":"26","author":"M Cortese","year":"2025","unstructured":"Cortese, M. et al. System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans. Nat. Immunol. 26, 116\u2013130 (2025).","journal-title":"Nat. Immunol."},{"key":"2309_CR40","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1222908","volume":"337","author":"C Dreyfus","year":"2012","unstructured":"Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343\u20131348 (2012).","journal-title":"Science"},{"key":"2309_CR41","first-page":"e00694","volume":"62","author":"SO Ali","year":"2018","unstructured":"Ali, S. O. et al. Evaluation of MEDI8852, an anti-influenza A monoclonal antibody, in treating acute uncomplicated influenza. Antimicrob. Agents Chemother. 62, e00694\u201318 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2309_CR42","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/infdis\/jix292","volume":"216","author":"CI Paules","year":"2017","unstructured":"Paules, C. I. et al. The hemagglutinin A stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses. J. Infect. Dis. 216, 356\u2013365 (2017).","journal-title":"J. Infect. Dis."},{"key":"2309_CR43","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","volume":"166","author":"NL Kallewaard","year":"2016","unstructured":"Kallewaard, N. L. et al. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166, 596\u2013608 (2016).","journal-title":"Cell"},{"key":"2309_CR44","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41586-021-04356-8","volume":"602","author":"JJ Guthmiller","year":"2022","unstructured":"Guthmiller, J. J. et al. Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature 602, 314\u2013320 (2022).","journal-title":"Nature"},{"key":"2309_CR45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/290713a0","volume":"290","author":"W Gerhard","year":"1981","unstructured":"Gerhard, W., Yewdell, J., Frankel, M. E. & Webster, R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290, 713\u2013717 (1981).","journal-title":"Nature"},{"key":"2309_CR46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.aaz8432","volume":"370","author":"CW Davis","year":"2020","unstructured":"Davis, C. W. et al. Influenza vaccine-induced human bone marrow plasma cells decline within a year after vaccination. Science 370, 237\u2013241 (2020).","journal-title":"Science"},{"key":"2309_CR47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-021-03647-4","volume":"595","author":"JS Turner","year":"2021","unstructured":"Turner, J. S. et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 595, 421\u2013425 (2021).","journal-title":"Nature"},{"key":"2309_CR48","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903\u20131915 (2007).","journal-title":"N. Engl. J. Med."},{"key":"2309_CR49","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00472-2","volume":"7","author":"L Grigoryan","year":"2022","unstructured":"Grigoryan, L. et al. Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice. NPJ Vaccines 7, 55 (2022).","journal-title":"NPJ Vaccines"},{"key":"2309_CR50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add5960","volume":"16","author":"M Prabhakaran","year":"2024","unstructured":"Prabhakaran, M. et al. Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primates. Sci. Transl. Med. 16, eadd5960 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2309_CR51","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","volume":"6","author":"A Radbruch","year":"2006","unstructured":"Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6, 741\u2013750 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"2309_CR52","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/eji.1830161018","volume":"16","author":"F Ho","year":"1986","unstructured":"Ho, F., Lortan, J. E., MacLennan, I. C. & Khan, M. Distinct short-lived and long-lived antibody-producing cell populations. Eur. J. Immunol. 16, 1297\u20131301 (1986).","journal-title":"Eur. J. Immunol."},{"key":"2309_CR53","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2021.12.026","volume":"185","author":"PA Mudd","year":"2022","unstructured":"Mudd, P. A. et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 185, 603\u2013613 (2022).","journal-title":"Cell"},{"key":"2309_CR54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","volume":"596","author":"JS Turner","year":"2021","unstructured":"Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109\u2013113 (2021).","journal-title":"Nature"},{"key":"2309_CR55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-022-04527-1","volume":"604","author":"W Kim","year":"2022","unstructured":"Kim, W. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature 604, 141\u2013145 (2022).","journal-title":"Nature"},{"key":"2309_CR56","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/pharmaceutics14020423","volume":"14","author":"JX Yang","year":"2022","unstructured":"Yang, J. X. et al. Recent advances in the development of Toll-like receptor agonist-based vaccine adjuvants for infectious diseases. Pharmaceutics 14, 423 (2022).","journal-title":"Pharmaceutics"},{"key":"2309_CR57","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492\u2013503 (2010).","journal-title":"Immunity"},{"key":"2309_CR58","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/v9070186","volume":"9","author":"A Vasou","year":"2017","unstructured":"Vasou, A., Sultanoglu, N., Goodbourn, S., Randall, R. E. & Kostrikis, L. G. Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: from synthetic PRR agonists to the potential of defective interfering particles of viruses. Viruses 9, 186 (2017).","journal-title":"Viruses"},{"key":"2309_CR59","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ni.3328","volume":"17","author":"O Sobolev","year":"2016","unstructured":"Sobolev, O. et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat. Immunol. 17, 204\u2013213 (2016).","journal-title":"Nat. Immunol."},{"key":"2309_CR60","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00583-w","volume":"7","author":"T Aydillo","year":"2022","unstructured":"Aydillo, T. et al. Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination. NPJ Vaccines 7, 160 (2022).","journal-title":"NPJ Vaccines"},{"key":"2309_CR61","first-page":"207","volume":"6","author":"KK Yam","year":"2015","unstructured":"Yam, K. K. et al. AS03-adjuvanted, very-low-dose influenza vaccines induce distinctive immune responses compared to unadjuvanted high-dose vaccines in BALB\/c mice. Front. Immunol. 6, 207 (2015).","journal-title":"Front. Immunol."},{"key":"2309_CR62","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.4049\/jimmunol.124.5.2414","volume":"124","author":"K Takatsu","year":"1980","unstructured":"Takatsu, K., Tominaga, A. & Hamaoka, T. Antigen-induced T cell-replacing factor (TRF). I. Functional characterization of a TRF-producing helper T cell subset and genetic studies on TRF production. J. Immunol. 124, 2414\u20132422 (1980).","journal-title":"J. Immunol."},{"key":"2309_CR63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0065-2776(08)01006-7","volume":"101","author":"K Takatsu","year":"2009","unstructured":"Takatsu, K., Kouro, T. & Nagai, Y. Interleukin 5 in the link between the innate and acquired immune response. Adv. Immunol. 101, 191\u2013236 (2009).","journal-title":"Adv. Immunol."},{"key":"2309_CR64","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","volume":"108","author":"N Chihara","year":"2011","unstructured":"Chihara, N. et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc. Natl Acad. Sci. USA 108, 3701\u20133706 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2309_CR65","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1182\/blood-2009-07-230631","volume":"115","author":"K Maeda","year":"2010","unstructured":"Maeda, K., Mehta, H., Drevets, D. A. & Coggeshall, K. M. IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. Blood 115, 4699\u20134706 (2010).","journal-title":"Blood"},{"key":"2309_CR66","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood.V85.2.487.487","volume":"85","author":"MM Kawano","year":"1995","unstructured":"Kawano, M. M., Mihara, K., Huang, N., Tsujimoto, T. & Kuramoto, A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 85, 487\u2013494 (1995).","journal-title":"Blood"},{"key":"2309_CR67","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1038\/leu.2014.61","volume":"28","author":"M Jourdan","year":"2014","unstructured":"Jourdan, M. et al. IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia 28, 1647\u20131656 (2014).","journal-title":"Leukemia"},{"key":"2309_CR68","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1128\/JVI.03509-12","volume":"87","author":"I Margine","year":"2013","unstructured":"Margine, I. et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J. Virol. 87, 4728\u20134737 (2013).","journal-title":"J. Virol."},{"key":"2309_CR69","doi-asserted-by":"crossref","first-page":"17221","DOI":"10.1073\/pnas.1920321117","volume":"117","author":"CP Arevalo","year":"2020","unstructured":"Arevalo, C. P. et al. Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies. Proc. Natl Acad. Sci. USA 117, 17221\u201317227 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2309_CR70","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1107","volume":"9","author":"N Kavian","year":"2020","unstructured":"Kavian, N. et al. Assessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults. Clin. Transl. Immunol. 9, e1107 (2020).","journal-title":"Clin. Transl. Immunol."},{"key":"2309_CR71","doi-asserted-by":"crossref","first-page":"914969","DOI":"10.3389\/fimmu.2022.914969","volume":"13","author":"TM Styles","year":"2022","unstructured":"Styles, T. M. et al. V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 clade C envelope Gp140 delays acquisition of heterologous clade C tier 2 challenges in Mamu-A*01 negative rhesus macaques. Front. Immunol. 13, 914969 (2022).","journal-title":"Front. Immunol."},{"key":"2309_CR72","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1002\/cpz1.465","volume":"2","author":"F Cuevas","year":"2022","unstructured":"Cuevas, F., Kawabata, H., Krammer, F. & Carre\u00f1o, J. M. An in vitro microneutralization assay for influenza virus serology. Curr. Protoc. 2, e465 (2022).","journal-title":"Curr. Protoc."},{"key":"2309_CR73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsb.2005.03.010","volume":"151","author":"C Suloway","year":"2005","unstructured":"Suloway, C. et al. Automated molecular microscopy: the new Leginon system. J. Struct. Biol. 151, 41\u201360 (2005).","journal-title":"J. Struct. Biol."},{"key":"2309_CR74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsb.2009.01.002","volume":"166","author":"GC Lander","year":"2009","unstructured":"Lander, G. C. et al. Appion: an integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. 166, 95\u2013102 (2009).","journal-title":"J. Struct. Biol."},{"key":"2309_CR75","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jsb.2012.09.006","volume":"180","author":"SH Scheres","year":"2012","unstructured":"Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519\u2013530 (2012).","journal-title":"J. Struct. Biol."},{"key":"2309_CR76","doi-asserted-by":"crossref","first-page":"e42166","DOI":"10.7554\/eLife.42166","volume":"7","author":"J Zivanov","year":"2018","unstructured":"Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife 7, e42166 (2018).","journal-title":"Elife"},{"key":"2309_CR77","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.cell.2019.04.036","volume":"177","author":"CW Davis","year":"2019","unstructured":"Davis, C. W. et al. Longitudinal analysis of the human B cell response to Ebola virus infection. Cell 177, 1566\u20131582 (2019).","journal-title":"Cell"},{"key":"2309_CR78","doi-asserted-by":"publisher","unstructured":"gktharp1. yerkes-gencore\/AS03_Akhtar_Amara_Final: AS03_Akhtar_Amara_Final (v1.0.0). Zenodo https:\/\/doi.org\/10.5281\/zenodo.17094473 (2025).","DOI":"10.5281\/zenodo.17094473"}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02309-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02309-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02309-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:20:22Z","timestamp":1761787222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02309-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":78,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2309"],"URL":"https:\/\/doi.org\/10.1038\/s41590-025-02309-1","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus vaccines (including cHAs) and influenza virus therapeutics which list F.K. and P.P. as coinventors and F.K. has received royalty payments from some of these patents. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, Castlevax, to develop SARS-CoV-2 vaccines. F.K. is cofounder and scientific advisory board member of Castlevax. F.K. has consulted for Merck, GSK, Sanofi, Curevac, Seqirus and Pfizer and is currently consulting for Third Rock Ventures, Gritstone and Avimex. The laboratory of F.K. is also collaborating with Dynavax on influenza vaccine development and with VIR on influenza virus therapeutics. J.H. and A.B.W. are consultants for Third Rock Ventures. The laboratory of A.B.W. received unrelated sponsored research agreements from Third Rock Ventures during the conduct of the study. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}